Document Detail


Early experience with enteric-coated mycophenolate sodium in de novo kidney transplant recipients.
MedLine Citation:
PMID:  15964340     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: We sought to evaluate the efficacy of enteric-coated mycophenolate sodium (EC-MPS) and the gastrointestinal (GI) adverse events in de novo kidney transplant recipients.
METHODS: This noncontrolled, retrospective review includes 22 de novo kidney transplant recipients. All patients received a standard course of basiliximab and were maintained on triple-drug therapy with EC-MPS, cyclosporine microemulsion (CsA), and prednisolone. The follow-up lasted 7.9 +/- 1.2 months. The incidence of GI adverse effects were compared with those of historical mycophenolate mofetil (MMF) studies.
RESULTS: The serum creatinine was maintained within 1.4 +/- 0.7 mg/dL. The 2-hour CsA postdose level was 1080 +/- 327 ng/mL initially and gradually tapered to 851 +/- 435 ng/mL. The daily EC-MPS dose was 1404 +/- 180 mg initially and gradually tapered to 1098 +/- 288 mg. The GI adverse effects at the daily dose of EC-MPS 1422 +/- 126 mg included dyspepsia 27%, acid regurgitation 18.2%, epigastralgia 9%, nausea 9%, vomiting 4.5%, and poor appetite 4.5%. In comparison those from historical MMF 2 g/d studies included dyspepsia 3.1% to 40%, epigastralgia 10%, nausea 3.7% to 34%, and vomiting 0.6% to 10.7%.
CONCLUSION: Immunosuppression with CsA, EC-MPS, and steroids maintains stable graft functions. Minimal dose reduction of EC-MPS decreases GI adverse events but without significance. EC-MPC and MMF have respective GI side effects; they can be used alternatively in patients with individual GI intolerance.
Authors:
H-R Chang; C-C Lin; J-D Lian
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Transplantation proceedings     Volume:  37     ISSN:  0041-1345     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-06-20     Completed Date:  2005-10-25     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2066-8     Citation Subset:  IM    
Affiliation:
Division of Nephrology, Department of Internal Medicine, Chung-Shan Medical University, Taichung, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cyclosporine / therapeutic use
Drug Therapy, Combination
Hematocrit
Humans
Immunosuppressive Agents / administration & dosage,  adverse effects,  therapeutic use
Kidney Transplantation / immunology*
Mycophenolic Acid / administration & dosage,  analogs & derivatives*,  therapeutic use
Platelet Count
Prednisolone / therapeutic use
Retrospective Studies
Tablets, Enteric-Coated
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Tablets, Enteric-Coated; 24280-93-1/Mycophenolic Acid; 50-24-8/Prednisolone; 59865-13-3/Cyclosporine; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diffuse vascular damage in a transplanted kidney: an indication for nuclear magnetic resonance?
Next Document:  The cost-effectiveness of basiliximab induction in "old-to-old" kidney transplant programs: Bayesian...